Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%+1.15%+23.89%-6.52% 68.85B
-0.54%+0.38%+36.12%+192.81% 52.13B
-3.65%+34.50%+34.50%+34.50% 43.46B
-0.58%-0.23%-52.36%-53.82% 41.24B
-2.93%+0.40%+59.97%-27.79% 30.41B
-3.77%-12.86%+90.31%-52.47% 24.53B
-1.36%-0.91%+70.42%+83.86% 23.42B
+3.99%+3.12%+3.87%+200.81% 19.75B
+0.26%-1.74%+70.47%+125.19% 16.57B
Average -0.99%-1.02%+37.47%+55.18% 35.6B
Weighted average by Cap. -1.19%-0.46%+30.59%+46.06%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-